FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Brendan Hussey

Principal JLS Fund

Thursday 5th February 2026

Panel Discussion: Bridging Innovation & Investment: De-Risking Disease-Modifying Neurodegenerative Therapies to Secure Investor Backing

3:30 pm

What does “de-risked” biology actually mean in AD/PD right now, and how does that differ for first-in-class versus best-in-class programs?
In today’s market, what milestones genuinely unlock the next cheque: target validation, Phase 1 biomarkers, early clinical signal, or differentiated strategy vs the competitive landscape?
How are investors underwriting differentiation in crowded spaces (e.g., brain-shuttle Aβ), and what must a Phase 1 package prove to stand out?
Beyond science, what determines investability: team quality, trial execution, commercial fit, and the ability to pivot, and why do these factors now carry more weight than ever?